188 related articles for article (PubMed ID: 16563945)
1. Risk constellations in patients with the metabolic syndrome: epidemiology, diagnosis, and treatment patterns.
Haffner SM
Am J Med; 2006 May; 119(5 Suppl 1):S3-9. PubMed ID: 16563945
[TBL] [Abstract][Full Text] [Related]
2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
3. Metabolic syndrome: treatment of hypertensive patients.
Israili ZH; Lyoussi B; Hernández-Hernández R; Velasco M
Am J Ther; 2007; 14(4):386-402. PubMed ID: 17667215
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials.
Abuissa H; Jones PG; Marso SP; O'Keefe JH
J Am Coll Cardiol; 2005 Sep; 46(5):821-6. PubMed ID: 16139131
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now?
Böhm M
Am J Cardiol; 2007 Aug; 100(3A):38J-44J. PubMed ID: 17666197
[TBL] [Abstract][Full Text] [Related]
6. The prevention of type 2 diabetes: what is the evidence?
Chiasson JL; Brindisi MC; Rabasa-Lhoret R
Minerva Endocrinol; 2005 Sep; 30(3):179-91. PubMed ID: 16208307
[TBL] [Abstract][Full Text] [Related]
7. Strategies in ongoing clinical trials to reduce cardiovascular disease in patients with diabetes mellitus and insulin resistance.
Mazzone T
Am J Cardiol; 2004 Jun; 93(11A):27C-31C. PubMed ID: 15178514
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
Vijan SG
J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
[TBL] [Abstract][Full Text] [Related]
9. Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition.
Leiter LA; Lewanczuk RZ
Am J Hypertens; 2005 Jan; 18(1):121-8. PubMed ID: 15691626
[TBL] [Abstract][Full Text] [Related]
10. The renin angiotensin system as a therapeutic target to prevent diabetes and its complications.
Vijayaraghavan K; Deedwania PC
Cardiol Clin; 2005 May; 23(2):165-83. PubMed ID: 15694745
[TBL] [Abstract][Full Text] [Related]
11. Metabolic syndrome.
Vitale C; Marazzi G; Volterrani M; Aloisio A; Rosano G; Fini M
Minerva Med; 2006 Jun; 97(3):219-29. PubMed ID: 16855517
[TBL] [Abstract][Full Text] [Related]
12. [Antihypertensive agents and the risk of new onset diabetes mellitus].
Kuzmanić D; Laganović M; Dika Z; Kos J; Pećin I
Lijec Vjesn; 2006; 128(11-12):336-41. PubMed ID: 17212194
[TBL] [Abstract][Full Text] [Related]
13. Strategies to prevent type 2 diabetes.
Abuissa H; Bel DS; O'keefe JH
Curr Med Res Opin; 2005 Jul; 21(7):1107-14. PubMed ID: 16004680
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular drugs as antidiabetic agents: evidence for the prevention of type 2 diabetes.
Macfarlane DP; Paterson KR; Fisher M
Diabetes Obes Metab; 2008 Jul; 10(7):533-44. PubMed ID: 18248492
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular risk: prevention and treatment of the metabolic syndrome.
Tuomilehto J
Diabetes Res Clin Pract; 2005 Jun; 68 Suppl 2():S28-35. PubMed ID: 15953504
[TBL] [Abstract][Full Text] [Related]
16. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.
Kolasinska-Malkowska K; Filipiak KJ; Gwizdala A; Tykarski A
Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):759-71. PubMed ID: 18510491
[TBL] [Abstract][Full Text] [Related]
17. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials).
Andraws R; Brown DL
Am J Cardiol; 2007 Apr; 99(7):1006-12. PubMed ID: 17398202
[TBL] [Abstract][Full Text] [Related]
18. Blocking the renin-angiotensin system: dual- versus mono-therapy.
Ravandi A; Teo KK
Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
[TBL] [Abstract][Full Text] [Related]
19. Management issues in the metabolic syndrome.
Deedwania PC; Gupta R
J Assoc Physicians India; 2006 Oct; 54():797-810. PubMed ID: 17214277
[TBL] [Abstract][Full Text] [Related]
20. A perspective on telmisartan and cardiovascular risk.
Giles TD
Rev Cardiovasc Med; 2007; 8(3):154-9. PubMed ID: 17938615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
